Evaluation of a Apo-1/Fas promoter polymorphism in Korean stroke patients.
- Author:
Jung Chul SEO
1
;
Sang Won HAN
;
Chang Sik YIN
;
Hyung Kyun KOH
;
Chang Hwan KIM
;
Ee Hwa KIM
;
Kang Hyun LEEM
;
Hyang Sook LEE
;
Hi Joon PARK
;
Soon Ae KIM
;
Bong Keun CHOE
;
Hee Jae LEE
;
Sung Vin YIM
;
Chang Ju KIM
;
Joo Ho CHUNG
Author Information
1. Department of Acupuncture and Moxibustion, College of Oriental Medicine, Kyungsan University, Gumi, Korea. acumox@hanmail.net
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
cerebrovascular accident;
CD95 antigen;
restriction fragment length polymorphism;
promoter regions
- MeSH:
Adult;
Aged;
Antigens, CD95/*genetics;
Cerebral Infarction/*genetics;
Comparative Study;
Female;
Gene Frequency;
Genotype;
Human;
Korea;
Male;
Middle Aged;
*Polymorphism (Genetics);
*Promoter Regions (Genetics)
- From:Experimental & Molecular Medicine
2002;34(4):294-298
- CountryRepublic of Korea
- Language:English
-
Abstract:
Apoptosis has been implicated in the pathogenesis of neurodegenerative diseases such as stroke and Alzheimer's disease. Apo-1/Fas gene is one of the mediators of apoptosis in stroke. MvaI polymorphism is the first polymorphic marker identified in the Apo-1/Fas gene promoter, which was typed by PCR and followed by MvaI digestion and gel electrophoresis. DNA isolated from peripheral blood collected from 91 stroke patients and 103 healthy blood donors was used for genotypes of GG, GA and AA by sequence specific primer PCR. MvaI polymorphism was examined based on Fas gene promotor region by restriction fragment length polymorphism (RFLP). The Fas-GG genotype was the least frequent in patients with stroke and healthy controls (P = 0.57). In normal Korean controls the MvaI polymorphism GA, AA and GG were 48.6%, 34.9% and 16.5%. In stroke patients were 56.2%, 29.6% and 14.2% respectively. And the allelic frequencies of MvaI*2 (G) allele were less frequent than MvaI*1 (A) allele in patients with stroke and healthy controls (P = 0.76). In normal Korean controls MvaI*1 (A) and MvaI*2 (G) alleles were 59.2% and 40.8%. In stroke patients were 57.6% and 42.4%, respectively. Our results, pending confirmation in a larger study, indicate that the Fas genotype may not appear to be a risk factor for stroke in Korean stroke patients.
